| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total revenue | 17,851 | 15,658 | 17,959 | 13,474 |
| Cost of goods sold | 8,324 | 5,870 | 8,375 | 9,456 |
| Research and development expenses | 4,467 | 5,992 | 2,998 | 2,961 |
| Selling, general and administrative expenses | 2,929 | 2,624 | 2,595 | 3,484 |
| Operating income (loss) | 2,131 | 1,172 | 3,991 | -2,427 |
| Financial expenses | 180 | 783 | - | - |
| Financial income | 288 | 272 | 151 | 522 |
| Other nonoperating expense | - | - | 299 | 367 |
| Financial income (expenses), net | 108 | -511 | -148 | 155 |
| Income (loss) before taxes on income | 2,239 | 661 | 3,843 | -2,272 |
| Taxes on income (tax benefit) | -116 | 497 | 607 | -69 |
| Net income (loss) | 2,355 | 164 | 3,236 | -2,203 |
| Earnings per share, basic | 0.03 | 0 | 0.04 | -0.03 |
| Earnings per share, diluted | 0.03 | 0 | 0.03 | -0.03 |
| Weighted average number of shares outstanding, basic | 79,281,685 | 78,663,884 | 73,549,745 | 73,308,281 |
| Weighted average number of shares outstanding, diluted | 80,814,564 | 81,271,610 | 81,217,068 | 73,308,281 |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)